Sie suchten nach: charm (Englisch - Maltesisch)

post-industrial charm
faxxinu post-industrijali

maintenance of clinical remission was evaluated in charm.
il-fatt jekk ġiex mantenut it-titjib kliniku ġie evalwat f’charm.

maintenance of clinical remission was evaluated in cd study iii (charm).
il-fatt jekk ġiex mantenut it-titjib kliniku ġie evalwat fi studju cd iii (charm).

in charm, 854 patients received open-label 80 mg at week 0 and 40 mg at week 2.
f’charm, 854 pazjent irċevew 80 mg f’ġimgħa 0 u 40 mg f’ġimgħa 2, open label.

when combining controlled portions of ten trials (i-ix and charm) and ongoing open label lp
ad kull1000 sena ta ’ pazjent fost pazjenti mogħtija kura kontrollata.

attending the university where dante and petrarch studied was a great experience in itself, not to mention the charm of the city and the bolognesi.
il-fatt li kont nattendi l-università fejn studjaw dante u petrarka kienet esperjenza kbira fiha innifisha, biex ma nsemmix il-ġibda tal-belt u tal-bolognesi.

however, after years of decline, the region is now rediscovering itself, and is starting to exploit its natural heritage along with its hospitality and charm.
madankollu, wara snin fejn kien sejjer lura, irreġjun issa qed jerġa’ jiskopri lilu nnifsu, u qed jibda jesplojtja l-patrimonju nazzjonali tiegħu flimkien ma’ l-ospita-lità u s-seħer tiegħu.

19 trudexa 80/ 40 mg and 160/ 80 mg compared to placebo and was seen at weeks 26 and 56 in charm as well among the adalimumab treatment groups compared to the placebo group.
(ibdq), u dan f’ pazjenti li ġew magħżula bl- addoċċ u ngħataw 80/ 40 mg u 160/ 80 mg trudexa meta mqabbel mal- plaċebo, u dan deher f’ ġimgħat 26 u 56 f’ charm, kif ukoll fil- gruppi tal- kura b’ adalimumab meta mqabbla mal- grupp tal- plaċebo. diċ

in charm, at week 4, 58% (499/854) of patients were in clinical response and were assessed in the primary analysis.
f’charm, f’ġimgħa 4, 58% (499/854) tal-pazjenti kellhom rispons kliniku u ġew assessjati fl-analiżi primarja.

during the controlled portions of ten trudexa trials at least 12 weeks in duration (i-ix and charm) in patients with moderately to severely active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and crohn’ s disease, malignancies, other than lymphoma and non-melanoma skin cancer, were observed at a rate (95% confidence interval) of 5.7 (3.3, 10.1) per 1000 patient-years among t
ad tumuri malinni u disturbi fit- tkattir taċ- ċelloli fil- limfa. ’ g ħ matul il- fażijiet kontrollati ta ’ għaxar provi ta ’ trudexa li damu sejrin mill- inqas 12 - il ġimgħa (i- ix u charm) fuq pazjenti li jbatu minn artrite rewmatika attiva minn moderata sa severa, artrite psorjatika, infjammazzjoni tal- vertebri li jirriżulta fil- vertebri jitwaħħlu flimkien (ankylosing spondylitis) u l- marda crohn (crohn’ s disease), tumuri malinni minbarra limfoma u kanċer tal- ġilda li im